Business Context and Reporting Period
Company: Bristol-Myers Squibb Company (BMS)
Filing Type: Form 8-K (Current Report)
Date of Report: August 9, 2023
Event: Announcement of Accelerated Share Repurchase (ASR) transactions.
Key Financial Metrics
This filing reports a specific capital allocation event rather than periodic financial performance metrics (e.g., revenue, profit, or cash flow).
- Share Repurchase Authorization: $4.0 billion aggregate Repurchase Price.
- Initial Settlement: BMS will receive Common Stock with an aggregate value of 85% of the Repurchase Price based on the closing share price on August 9, 2023.
- Payment Date: August 10, 2023.
- Counterparties: Bank of America, N.A., Citibank, N.A., JPMorgan Chase Bank, National Association, and Morgan Stanley & Co. LLC.
Material Changes
The filing details a new material event: the execution of ASR agreements to repurchase $4.0 billion of common stock. This action is part of a previously announced board-authorized, multi-year share repurchase program. The filing does not provide comparative financial data against prior periods as it is a current event report.
Outlook, Risks, and Unusual Items
Transaction Mechanics: The final number of shares repurchased will be determined by the volume-weighted average price of the Common Stock during the term of the ASR transactions, less a discount. Upon final settlement, BMS may receive additional shares or, under certain circumstances, be required to deliver shares or make a cash payment to the banks.
Termination: The ASR transactions are scheduled to terminate in the fourth quarter of 2023, though they may conclude earlier at the election of the applicable bank.
Risks: The filing notes standard provisions for adjustments, acceleration, extension, or early termination by the banks.
Investor Verification Checklist
- Verify the exact number of shares received in the initial 85% settlement on August 10, 2023.
- Monitor the volume-weighted average price of BMS stock during the ASR term to estimate the final share count.
- Confirm the remaining balance of the multi-year share repurchase program after this $4.0 billion transaction.
- Review future filings for the final settlement details and any cash adjustments required in Q4 2023.